A study led by Gordon Mills, M.D., Ph.D., professor and chair of Systems Biology at The University of Texas MD Anderson Cancer Center with Lydia Cheung, Ph.D. as the first author, points to cellular mutations in the gene PIK3R1 which activate ERK and JNK, thus allowing tumor growth. Results from the study, were published in this month’s issue of Cancer Cell.
Standard therapies today center on the cancer gene as a whole. Mills’ and Cheung’s study suggests that targeted therapies may need to focus on the gene mutation specifically.
Read the full press release here.
Study mentioned:
Cancer Cell. 2014 Oct 1. pii: S1535-6108(14)00349-3. doi: 10.1016/j.ccell.2014.08.017. [Epub ahead of print]
Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors.
No comments:
Post a Comment